MedTrace Logo

Revealing Protective Immunity to Influenza Using Systems Immunology

NCT06501963 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-03-30

Study results available
· View outcomes & findings →

Summary

The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray. Better understanding why this vaccine does not work as well in adults as it does in children may help design better influenza vaccines.

Conditions

Interventions

BIOLOGICAL

Live Attenuated Influenza Vaccine

The FDA-approved live attenuated seasonal influenza vaccine (LAIV) (FluMist®, AstraZeneca) is licensed in the US for people 2-49 years of age. The approved seasonal LAIV at the time of study enrollment will be obtained from the manufacturer. LAIV will be administered by a study nurse or health care provider at the Hope Clinic as a single 0.2 milliliter (mL) dose given as 0.1 mL spray in each nostril.

Sponsors & Collaborators

  • Boston University

    collaborator OTHER

  • Emory University

    lead OTHER

Principal Investigators

  • Daniel Graciaa, MD, MPH, MSc · Emory University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2025-04-01
Completion
2025-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06501963 on ClinicalTrials.gov